Patients with noncastrate advanced,
recurrent, or metastatic prostate cancer
Metastatic
disease
De novo or
after RP, RT,
or ADT
High or
low risk
ADT +
apalutamide
De novo
ADT +
docetaxel
High volume
disease and
chemotherapy
candidate
ADT +
enzalutamide
ADT +
abiraterone +
predisnone/
prednisolone
2
Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, Nguyen PL, Loblaw DA,
Tagawa ST, Gillessen S, Morgan TM. Clinically localized prostate cancer: ASCO clinical practice
guideline endorsement of an American Urological Association/American Society for Radiation
Oncolog y/Society of Urologic Oncolog y guideline. Journal of Clinical Oncolog y. 2018 Nov
10;36(32):32518.
